1. Northern England Strategic Clinical Network Conference 15 th May 2015 Update - Head and Neck Site Specific Group Eleanor Aynsley Clinical Oncologist

2. Robotic surgery (TORS) Currently being used in Newcastle by Mr Vin Paleri for selected cases for selected oropharynx cases, approx 50 cases operated on Presented findings at 1 international and 2 national meetings Quicker operation time, shorter inpatient stay Can operate on cases may not otherwise be able to Hope to be operational in James Cook and Sunderland in near future

4. Intensity Modulated Radiotherapy IMRT Standard for complex head and neck cases in Newcastle and Middlesbrough Still not in Carlisle, although offered to go to Newcastle Rolling out IMRT for all head and neck cases

5. CF 71 year old lady Presented with lump in left neck PMH of hypertension and OA Smoked 10 a day, occasional alcohol PS 2 Histology squamous cell ca

7. Had 3 cycles of neoadjuvant chemotherapy (cisplatin and 5FU) with a partial response 65 Gy in 30 fractions to PTV1 which was the larynx and left levels Ib to V and 54 Gy in 30 fractions to PTV2 which was right levels II to IV plus 3/6 weekly Cisplatin chemotherapy cycles. Was dizzy during treatment and required peg feeding Following treatment managing soft diet

12. Survivorship Recognition important due to long term side effects of radiotherapy such as dysphagia and after effects of surgery eg laryngectomy affecting speech and body image National Cancer Survivorship Initiative (collaborative between NHS England and Macmillan) has 4 main aims: 1.Holistic needs assessment (HNA) to be done on all patients at diagnosis and any other time appropriate (key times-post treatment and again 6 months after treatment ) All 2.Treatment summary Sunderland 3.Cancer care review-by GP 4.Health and wellbeing clinics/educational events /signposting patients

13. Holistic needs assessment Should cover the following : Addressing any physical or practical concerns Signposting to either local or national support groups Information about local Health and Wellbeing Clinics, Education Events or self management courses as available in your area. Referral to Allied Healthcare Professionals for support if required Advice related to lifestyle i.e. Stop smoking services Information or referral to an appropriate physical activity programme Information or referral for advice on diet and nutrition Referral for counselling or psychological support Support related to work and finance concerns Support for spiritual needs

14. Clinical trials Head and neck 5000 recruited very well across network Other trials helping quality assurance of radiotherapy and surgery

15. SEND The role of selective neck dissection used electively in patients with early oral squamous cell carcinoma (tumour stage T1 and T2) and no clinical evidence of lymph node metastases in the neck. T1/T2 N0 SqCC oral cavity Randomisation 1:1 Resection of primary with simultaneous neck dissection at presentation Resection of primary tumour alone and salvage treatment of neck if neck metastases develop CI: Prof Ian Hutchison → plan for merged data analysis with similar RCT Tata Memorial Hospital, Mumbai – 330 patients/460 in total (of 650)

16. ART-DECO A Multicentre Randomised Study of Dose Intensity Modulated Radiotherapy Versus Standard Dose Radiotherapy in Patients with Locally Advanced Laryngeal and Hypopharyngeal Cancers. Induction chemotherapy [Optional by centre] Diagnosis of locally advanced squamous cell cancer of the larynx or hypopharynx requiring definitive Treatment With RT or chemoradiotherapy Dose escalated IMRT 67.2Gy in 28 fractions to the involved site and nodal groups 56Gy in 28 fractions to nodal areas at risk of harbouring microscopic disease. Standard dose IMRT 65Gy in 30 fractions to involved site and nodal groups 54 Gy in 30 fractions to nodal areas at risk of harbouring microscopic disease. Patients may receive a maximum of 3 (21 day) cycles of platinum based induction chemotherapy prior to radiotherapy Concomitant cisplatin (Day 1 and Day 29) [All patients] R CI: Prof Chris Nutting RMH

17. Screen 910 biopsies from T3-T4NO, T1-4,N1-2 oropharynx SCC HPV+ on PCR AND p16+ on immunohistochemistry (Central MHRA-approved Laboratory) Randomise 330 patients 1:1 Control Concomitant Cisplatin + Radiotherapy (70 Gy in 30 F) Study Concomitant Cetuximab + Radiotherapy (70 Gy in 30 F) Stratified by Centre, Tumour site, T & N stage, Smoking status 10% Lost to follow up (n=17) 10% Lost to follow-up (n=17) Analysed (n= 148) Follow-up: 2 years Primary outcomes: Overall survival Severe Acute and Late Toxicity: using CTCAE grading, including skin rashes, mucositis Secondary outcomes: Health economics using EQ-5D, Early toxicity, Quality of life: using EORTC general and head neck specific modules, Swallowing: using MDADI questionnaire and gastrostomy - dependency rates, Mortality (cause of death), disease free survival, recurrence, metastases. Key: HPV – Human Papilloma Virus PCR – polymerase chain reaction CTCAE – Common Terminology Criteria for Adverse Events version 3.0 MDADI – MD Anderson Dysphagia Inventory De-escalate

18. PATHOS Trial schema No adjuvant treatment HPV positive OPSCC T1-3 N0-N2b Low risk Pathology assessment Intermediate risk High risk B160Gy in 30# (control) B250Gy in 25# (test) C160Gy in 30#+Cisplatin (control) C260Gy in 30# (test) Transoral Surgery (TLM/TORS) +neck dissection Endpoints: swallowing function (MDADI) at 12months (phase II), overall survival (phase III) A B C Randomise

19. Any questions?